FDA Rifampin Injection Shortage: Distributor Impact 2025

FDA Reports Ongoing Rifampin Injection Shortage – Distribution Impact for Wholesalers

The FDA Drug Shortages Database lists rifampin injection in active shortage status as of January 2025, with Fresenius Kabi USA as the sole manufacturer reporting supply disruption. This shortage directly affects wholesale drug distributor allocation strategies and specialty pharmacy sourcing for tuberculosis treatment, particularly for hospitals managing disseminated TB and meningitis cases where oral rifampin cannot substitute for IV administration.

Regulatory Context

The FDA maintains the Drug Shortages Database under authority of the Food and Drug Administration Safety and Innovation Act (FDASIA), codified in Section 506C of the Federal Food, Drug, and Cosmetic Act. Manufacturers must notify FDA at least six months prior to a discontinuation or interruption in production of medically necessary drugs. The agency defines a drug shortage as "a period of time when the demand or projected demand for a medically necessary drug in the United States exceeds its supply."

Rifampin injection qualifies as medically necessary because it treats serious bacterial infections where alternative therapies are inadequate or unavailable. The injectable formulation serves patients who cannot tolerate oral rifampin due to gastrointestinal complications, malabsorption disorders, or critical care settings requiring IV administration. The FDA does not include rifampin injection on the Essential Medicines List, but CDC guidelines classify it as first-line therapy for tuberculosis meningitis and disseminated TB infections.

Shortage Details and Timeline

Affected Product: Rifampin for Injection, 600 mg single-dose vials

Manufacturer: Fresenius Kabi USA (NDC 63323-517-61)

Shortage Status: Active as of January 15, 2025

Reported Reason: Manufacturing delay impacting production capacity

Estimated Resolution: Fresenius Kabi reports resumed manufacturing with product availability expected by Q2 2025. FDA has not provided an independent estimated resolution date.

No alternative manufacturers supply rifampin injection in the U.S. market. Fresenius Kabi acquired the product line from Sandoz in 2020 and remains the sole FDA-approved source. The agency lists no therapeutically equivalent alternatives in injectable form.

FDA Mitigation Actions

FDA exercised enforcement discretion to facilitate importation of foreign-approved rifampin injection products through the temporary importation pathway outlined in FDA Guidance for Industry: "Temporary Importation of Certain FDA-Regulated Products During a Drug Shortage." This mechanism allows wholesalers and hospitals to source product manufactured for non-U.S. markets when domestic supply falls below demand.

As of January 20, 2025, FDA has not issued specific compounding guidance for rifampin injection under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Hospital pharmacies seeking to compound rifampin IV preparations operate under existing USP Chapter 797 requirements for sterile compounding but lack FDA-endorsed formulation guidance for this specific product.

Impact on Wholesale Distribution Operations

Allocation Protocol Requirements: Wholesale drug distributors holding existing rifampin injection inventory must implement fair and transparent allocation systems when demand exceeds supply. The Drug Supply Chain Security Act (DSCSA) does not explicitly regulate allocation practices, but state boards of pharmacy in California, New York, and Florida require wholesalers to document allocation methodologies during shortage periods to prevent price gouging under state emergency provisions.

Trading Partner Verification: Distributors sourcing rifampin injection through FDA's temporary importation pathway must verify that foreign-manufactured product meets USP standards and includes English-language labeling per 21 CFR 201.15. This adds verification steps to standard DSCSA transaction documentation requirements under 21 USC 360eee-1.

Inventory Reporting: Large wholesale distributors supplying hospital systems should expect increased frequency of inventory status requests from specialty pharmacy procurement teams. Unlike routine drug ordering, shortage conditions trigger daily or twice-daily allocation updates in most hospital contracting agreements.

Cold Chain Considerations: Rifampin injection requires storage at 20-25°C (68-77°F) with excursions permitted to 15-30°C per USP Controlled Room Temperature standards. Product sourced through importation channels may arrive with different temperature logging documentation than domestic product. Distributors must validate that imported units maintained required storage conditions throughout the foreign supply chain before accepting product into U.S. distribution networks.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — the baseline requirement for entities handling prescription drug products during shortage-driven allocation scenarios. However, the average compliance score of 51/100 indicates that fewer than half of tracked entities maintain comprehensive licensure and accreditation signals beyond baseline FDA registration.

During drug shortage periods, specialty pharmacy procurement teams typically prioritize distributors with stronger compliance postures for allocation requests. The directory's score distribution reveals that only 309 entities (24%) score in the "Good" or "Excellent" range (60+ points), meaning these distributors maintain state licensure in 15+ jurisdictions, hold NABP accreditation, or demonstrate clean enforcement records. The remaining 957 entities (75%) fall into "Fair" or lower tiers, reflecting limited geographic coverage or incomplete verification data.

Rifampin injection's shortage status creates specific risk for distributors operating under allocation protocols without documented compliance systems. Of the 73 entities in ColdChainCheck's database with FDA recalls on record, 18 involve temperature deviation or storage condition failures — the same compliance dimension stressed by rifampin's USP Controlled Room Temperature requirements. Distributors sourcing product through FDA's temporary importation pathway should verify cold chain documentation against their existing quality management system capabilities before accepting foreign-manufactured units.

Compliance Actions for QA and Procurement Teams

Verify distributor FDA registration status: Use the ColdChainCheck directory to confirm that your rifampin injection trading partners hold current FDA establishment registrations. The directory cross-references FDA's publicly available registration database (last updated January 2025) and flags entities with lapsed or suspended registrations.

Check geographic licensure coverage: If sourcing rifampin injection from a new distributor due to allocation constraints, verify the entity holds active wholesale drug distributor licenses in your state. ColdChainCheck tracks state-level licensure across all 50 states plus DC and Puerto Rico. Entities with limited state coverage (scored below 15 points in the State Licenses dimension) may lack legal authority to distribute into your facility's jurisdiction.

Review recall history before allocation agreements: The directory flags entities with FDA recalls on record. During shortage periods when procurement teams evaluate secondary distributors, review whether potential trading partners have prior enforcement actions related to storage conditions, DSCSA compliance, or misbranded products. Filter the directory by "Entities with Recalls" to identify this subset.

Monitor NABP accreditation for specialty distributors: Only 63 entities in the directory hold NABP accreditation (formerly VAWD), representing 5% of tracked distributors. NABP-accredited entities undergo third-party inspection of their quality systems and DSCSA compliance infrastructure. For high-risk products like rifampin injection requiring temperature-controlled storage, NABP accreditation provides additional assurance beyond FDA registration alone.

ColdChainCheck tracks FDA drug shortage alerts and enforcement actions affecting wholesale distributors. See the Compliance Guides section for related coverage of DSCSA requirements during supply chain disruptions and temperature deviation reporting obligations under 21 CFR Part 211.

Disclaimer: This article provides informational content based on publicly available FDA data and regulatory guidance. It does not constitute legal or compliance advice. Entities should consult qualified regulatory counsel and verify all compliance requirements with the appropriate federal and state agencies.